Lumos Diagnostics Holdings
Lumos Diagnostics Holdings specializes in the development, manufacture, and distribution of point-of-care diagnostic tests and associated readers. The company is positioned as a leader in rapid diagnostics, offering unique solutions like FebriDx, which aids in differentiating bacterial from viral infections at the point of care.
Short position
Lumos Diagnostics Holdings (ASX:LDX) has 0.00% of its shares on issue reported as short positions as of 5 Oct 2026, or about 5,059 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.87% in June 2022. LDX is classified in the Health Care Equipment & Services industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Lumos Diagnostics Holdings (LDX) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in USD, the reporting currency
- Revenue
- 13.2Mvs 12.5M (FY25)
- Yahoo Finance, as at 29 Sep 2026
- NPAT
- −5.0Mvs −7.2M (FY25)
- Yahoo Finance, as at 29 Sep 2026
- EPS (diluted)
- −0.006vs −0.011 (FY25)
- Yahoo Finance, as at 29 Sep 2026
- Rev YoY
- +5.5%FY
- EPS YoY
- n/aTTM
Key ratios
Year to 30 Jun 2026 (FY); balance sheet at 30 Jun 2026; prices to 9 Oct 2026
- Gross margin
- 60.1%
- Operating margin
- −106.7%
- Net margin
- −37.5%
- FCF margin
- −11.6%
- ROE
- −34.1%
- ROA
- −16.1%
- FCF conversion
- n/a
- Net cash (excl. leases)
- USD 15.4M
- Net debt / EBITDA
- n/a
- Current ratio
- 1.5×
- Interest cover
- −9.0×
- Cash dividends paid / net profit
- n/a
- Market cap
- $94.4M
- P/E
- n/a (reports in USD)
- P/B
- n/a (reports in USD)
Ratios use the reporting currency (USD); market cap is in AUD. Source: Yahoo Finance, as at 29 Sep 2026.
Financial statements
Figures in USD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | 13.2M | 12.5M | 11.1M | 10.5M |
| Gross profit | 7.9M | 7.9M | 7.1M | 6.0M |
| Operating income | −14.1M | −7.8M | −7.1M | −9.5M |
| EBITDA | −850.0K | −4.6M | −5.4M | −4.9M |
| EBIT | −3.4M | −7.2M | −8.1M | −8.6M |
| Interest expense | 1.6M | 20.0K | 507.0K | 371.0K |
| Pretax income | −5.0M | −7.2M | −8.6M | −9.0M |
| Tax | 0 | 0 | 0 | 0 |
| NPAT | −5.0M | −7.2M | −8.6M | −9.0M |
| Net interest income | −2.0M | −526.0K | −1.1M | −791.0K |
| EPS basic | −0.006 | −0.011 | −0.017 | −0.036 |
| EPS diluted | −0.006 | −0.011 | −0.017 | −0.036 |
| Shares | 944.4M | 748.5M | 512.9M | 329.8M |
Financial reports
The company's own filings, newest first
- FY26 Appendix 4EAnnual Results26 Aug 2026via asx_announcements
- FY26 Annual ReportAnnual Report26 Aug 2026via asx_announcements
- FY26 Full Year Results AnnouncementFull Year Results26 Aug 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report27 Jul 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report20 Apr 2026via asx_announcements
- Appendix 4D and Half Year ReportHalf Year Results27 Feb 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report29 Jan 2026via asx_announcements
- MST Access | FebriDx CLIA waiver submissionFinancial Report31 Dec 2025via crawler
- Constitution of Lumos Diagnostics Holdings LimitedFinancial Report31 Dec 2025via crawler
- Long Term Incentive Plan RulesFinancial Report31 Dec 2025via crawler
Showing 10 of 77 reports